The current shortage of the narcotic analgesic Buprenorphine CAS# 52485-79-7, also known as the brand name Buprenex, has created a significant concern. As an injectable medication administered to treat moderate to severe pain, Buprenorphine is not only used for pain management, it is also used to treat addiction to narcotic drugs through a rapid detoxification system.
Also considered an opioid, Buprenorphine should not be dispensed to anyone under age 13, and caution should be taken as this medication has a high potential for becoming addictive. Buprenorphine is quite unique in that it has partial agonist and antagonist actions. This means is that the use of Buprenorphine can both stimulate opiate receptors of the brain and provide substantial pain relief. The higher dosages of Buprenorphine are effective for detoxification programs, as once the dosage is increased significantly the antagonist properties are brought out, which in turn block the opiate receptors of the brain.
The varied use of Buprenorphine makes this potentially addictive pain medication a common choice for patients in need of opiate withdrawal. While some practitioners are concerned that the use of Buprenorphine as a detoxification drug can lead to a new addiction to Buprenorphine, it is still a commonly used substance in many major drug detox programs.
The shortage of Buprenorphine is of great concern for hospitals, physicians and rehabilitation centers worldwide, and many manufacturers do not see new shipments until at least January 2014, if not later in 2014.
LGM Pharma can supply Buprenorphine for companies operating in the compounding industry, research centers or development laboratories. As the exclusive distributor of TAPI products for the US pharmacy compounding market, LGM Pharma also provides the Buprenorphine TEVA API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.